This study adds to the understanding of the early complications associated with cardiovascular implantable electronic devices (CIEDs) and the institutional variability in the quality of CIED implantation.
A systematic review compared the safety and efficacy of prasugrel and ticagrelor in patients with ACS undergoing PCI.
Having atrial fibrillation, using home oxygen, having severe lung disease, or having a permanent pacemaker were predictive of lower health status after transcatheter mitral valve repair.
While wearable technology can provide substantial patient benefit, these devices carry significant privacy and security risks.
For cardiac surgical patients, the likelihood of readmission has no association with day of discharge.
Coronary computed tomography angiography is a reliable tool to assess long-term cardiovascular risk in suspected CCS.
Single-stage complete coronary revascularization appears to be superior to culprit-only lesion intervention in multivessel disease ACS.
Transcatheter mitral-valve repair results in a lower rate of hospitalization and lower all-cause mortality than medical therapy alone among patients with heart failure and moderate-to-severe secondary mitral regurgitation who remain symptomatic despite the use of guideline-directed medical therapy.
The safety risk of dermatoscope magnets in patients with cardiovascular implanted electronic devices was examined.
There is no difference between heparin and bivalirudin in terms of platelet aggregation or coagulation markers after pretreatment with ticagrelor in patients undergoing PPCI.
